BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 16055380)

  • 1. Peak-dose dyskinesia; an acceptable price for mobility in late-stage Parkinson's disease?
    Wenzelburger R
    Clin Neurophysiol; 2005 Sep; 116(9):1997-8. PubMed ID: 16055380
    [No Abstract]   [Full Text] [Related]  

  • 2. Chewing-induced blepharospasm in Parkinson's disease.
    Spitz M; Sasse E; Vasconcellos LF; de Souza E Silva D; Pereira JS
    J Neurol Sci; 2016 Dec; 371():15-16. PubMed ID: 27871438
    [No Abstract]   [Full Text] [Related]  

  • 3. Serotonergic involvement in levodopa-induced dyskinesias in Parkinson's disease.
    Cheshire PA; Williams DR
    J Clin Neurosci; 2012 Mar; 19(3):343-8. PubMed ID: 22249009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacology of levodopa-induced dyskinesia in parkinsonian patients.
    Rascol O; Brefel-Courbon C; Descombes S; Montastruc JL
    Adv Neurol; 1999; 80():485-90. PubMed ID: 10410760
    [No Abstract]   [Full Text] [Related]  

  • 5. NMDA antagonist memantine improves levodopa-induced dyskinesias and "on-off" phenomena in Parkinson's disease.
    Varanese S; Howard J; Di Rocco A
    Mov Disord; 2010 Mar; 25(4):508-10. PubMed ID: 20014061
    [No Abstract]   [Full Text] [Related]  

  • 6. Mechanisms of motor complications in treatment of Parkinson's disease.
    Kumar A; Huang Z; de la Fuente-Fernández R
    Adv Neurol; 2003; 91():193-201. PubMed ID: 12442678
    [No Abstract]   [Full Text] [Related]  

  • 7. Unexpected improvement in levodopa-induced dyskinesia and on-off phenomena after introduction of memantine for treatment of Parkinson's disease dementia.
    Vidal EI; Fukushima FB; Valle AP; Villas Boas PJ
    J Am Geriatr Soc; 2013 Jan; 61(1):170-2. PubMed ID: 23311565
    [No Abstract]   [Full Text] [Related]  

  • 8. Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders.
    Voon V; Fernagut PO; Wickens J; Baunez C; Rodriguez M; Pavon N; Juncos JL; Obeso JA; Bezard E
    Lancet Neurol; 2009 Dec; 8(12):1140-9. PubMed ID: 19909912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Parkinson's disease].
    Yokochi M
    Ryoikibetsu Shokogun Shirizu; 1999; (27 Pt 2):5-14. PubMed ID: 10434578
    [No Abstract]   [Full Text] [Related]  

  • 10. [Continuous dopaminergic stimulation, pulsatile dopaminergic stimulation].
    Destée A; Bordet R
    Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S69-82. PubMed ID: 12690666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of later phases of Parkinson disease].
    Tison F
    Rev Neurol (Paris); 2008 Apr; 164 Spec No 2():F85-8. PubMed ID: 18680823
    [No Abstract]   [Full Text] [Related]  

  • 12. Medications for Parkinson's disease.
    Whitney CM
    Neurologist; 2007 Nov; 13(6):387-8. PubMed ID: 18090719
    [No Abstract]   [Full Text] [Related]  

  • 13. [Diagnosis and therapy of Parkinson's disease].
    Wittstock M; Benecke R
    MMW Fortschr Med; 2005 May; 147 Spec No 2():28-31. PubMed ID: 15968869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lees' syndrome: a case series.
    Becker N; Munhoz RP; Teive HA
    Arq Neuropsiquiatr; 2011 Oct; 69(5):756-9. PubMed ID: 22042176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rehabilitation goals and strategies in Parkinson's disease.
    Ceravolo MG
    Eur J Phys Rehabil Med; 2009 Jun; 45(2):205-8. PubMed ID: 19532108
    [No Abstract]   [Full Text] [Related]  

  • 16. [Updates in practical neurology--I. The principles of modern levodopa therapy in Parkinson's disease].
    Klivényi P; Vécsei L
    Ideggyogy Sz; 2007 Jan; 60(1-2):61-4. PubMed ID: 17432097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine].
    Montastruc JL; Schmitt L; Bagheri H
    Rev Neurol (Paris); 2003 Apr; 159(4):441-3. PubMed ID: 12773874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case of hedonistic homeostatic dysregulation.
    Kessel BL
    Age Ageing; 2006 Sep; 35(5):540-1. PubMed ID: 16799178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous dopaminergic therapy in Parkinson disease: time to stride back?
    Stoessl AJ
    Ann Neurol; 2010 Jul; 68(1):3-5. PubMed ID: 20583222
    [No Abstract]   [Full Text] [Related]  

  • 20. [Drug therapy of Parkinson's disease].
    Myllylä V
    Duodecim; 1997; 113(18):1827-34. PubMed ID: 10892076
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.